BRAF and colorectal carcinoma: According to the European Society for Medical Oncology (ESMO), testing for RET fusions is recommended for patients with metastatic CRC who have right-sided, MSI-high, and RAS/BRAF wild-type tumors, as they would probably benefit from precision medicine regimens as mentioned above [44].